Cargando…

Distinct serum metabolomics profiles associated with malignant progression in the Kras(G12D) mouse model of pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths worldwide with less than a 6% 5-year survival rate. PDAC is associated with poor prognosis based on the late stage diagnosis of the disease. Current diagnostic tests lack the sensitivity and specificity...

Descripción completa

Detalles Bibliográficos
Autores principales:	LaConti, Joseph J, Laiakis, Evagelia C, Mays, Anne Deslattes, Peran, Ivana, Kim, Sung Eun, Shay, Jerry W, Riegel, Anna T, Fornace, Albert J, Wellstein, Anton
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315147/ https://www.ncbi.nlm.nih.gov/pubmed/25923219 http://dx.doi.org/10.1186/1471-2164-16-S1-S1

Ejemplares similares

Addition of metabolomics to the omics spectrum for cancer biomarker development– demonstration with the KrasG12D mouse model for pancreatic carcinoma
por: Laiakis, Evagelia C, et al.
Publicado: (2014)

Tissue and Serum microRNAs in the Kras(G12D) Transgenic Animal Model and in Patients with Pancreatic Cancer
por: LaConti, Joseph J., et al.
Publicado: (2011)

Metabolomic Analysis in Severe Childhood Pneumonia in The Gambia, West Africa: Findings from a Pilot Study
por: Laiakis, Evagelia C., et al.
Publicado: (2010)

Distinct Response of Circulating microRNAs to the Treatment of Pancreatic Cancer Xenografts with FGFR and ALK Kinase Inhibitors
por: Peran, Ivana, et al.
Publicado: (2022)

Serum Metabolomic Alterations Associated with Cesium-137 Internal Emitter Delivered in Various Dose Rates
por: Li, Heng-Hong, et al.
Publicado: (2020)

Single-Molecule Real-Time (SMRT) Full-Length RNA-Sequencing Reveals Novel and Distinct mRNA Isoforms in Human Bone Marrow Cell Subpopulations
por: Deslattes Mays, Anne, et al.
Publicado: (2019)

Impact of inflammatory signaling on radiation biodosimetry: mouse model of inflammatory bowel disease
por: Mukherjee, Sanjay, et al.
Publicado: (2019)

Lipidomic Signatures of Nonhuman Primates with Radiation-Induced Hematopoietic Syndrome
por: Pannkuk, Evan L., et al.
Publicado: (2017)

Author Correction: Lipidomic Signatures of Nonhuman Primates with Radiation-Induced Hematopoietic Syndrome
por: Pannkuk, Evan L., et al.
Publicado: (2019)

Effects of Low Dose Space Radiation Exposures on the Splenic Metabolome
por: Laiakis, Evagelia C., et al.
Publicado: (2021)

Biofluid Metabolomics and Lipidomics of Mice Exposed to External Very High-Dose Rate Radiation
por: Pannkuk, Evan L., et al.
Publicado: (2022)

Effects of Genetic Variation on Urinary Small Molecule Signatures of Mice after Exposure to Ionizing Radiation: A Study of p53 Deficiency
por: Pannkuk, Evan L., et al.
Publicado: (2020)

KRAS-related noncoding RNAs in pancreatic ductal adenocarcinoma
por: Yu, Shuang-Ni, et al.
Publicado: (2016)

Temporal Effects on Radiation Responses in Nonhuman Primates: Identification of Biofluid Small Molecule Signatures by Gas Chromatography–Mass Spectrometry Metabolomics
por: Pannkuk, Evan L., et al.
Publicado: (2019)

Correction: Recurrence of Early Stage Colon Cancer Predicted by Expression Pattern of Circulating microRNAs
por: Shivapurkar, Narayan, et al.
Publicado: (2014)

Recurrence of Early Stage Colon Cancer Predicted by Expression Pattern of Circulating microRNAs
por: Shivapurkar, Narayan, et al.
Publicado: (2014)

Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
por: Liu, Yu-Huei, et al.
Publicado: (2022)

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
por: Zhang, Zining, et al.
Publicado: (2023)

Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2023)

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
por: Gurreri, Enrico, et al.
Publicado: (2023)

KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Notch1 Is Not Required for Acinar-to-Ductal Metaplasia in a Model of Kras-Induced Pancreatic Ductal Adenocarcinoma
por: Avila, Jacqueline L., et al.
Publicado: (2012)

Metabolic Phenotyping Reveals a Lipid Mediator Response to Ionizing Radiation
por: Laiakis, Evagelia C., et al.
Publicado: (2014)

Serum lipidomic analysis from mixed neutron/X-ray radiation fields reveals a hyperlipidemic and pro-inflammatory phenotype
por: Laiakis, Evagelia C., et al.
Publicado: (2019)

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
por: Luchini, Claudio, et al.
Publicado: (2020)

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
por: Ashok Kumar, Prashanth, et al.
Publicado: (2023)

Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma
por: Yousef, Abdelrahman, et al.
Publicado: (2023)

Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
por: Cao, Ying-Ying, et al.
Publicado: (2023)

Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features
por: PENG, JIE, et al.
Publicado: (2013)

Differential Effects of Dietary Macronutrients on the Development of Oncogenic KRAS-Mediated Pancreatic Ductal Adenocarcinoma
por: Zhu, Liang, et al.
Publicado: (2022)

Metachronous primary lung adenocarcinomas harboring distinct KRAS mutations
por: Hu, Yan, et al.
Publicado: (2020)

Hepatic lipid signatures of little brown bats (Myotis lucifugus) and big brown bats (Eptesicus fuscus) at early stages of white-nose syndrome
por: Pannkuk, Evan L., et al.
Publicado: (2021)

Disruption of p16 and Activation of Kras in Pancreas Increase Ductal Adenocarcinoma Formation and Metastasis in vivo
por: Qiu, Wanglong, et al.
Publicado: (2011)

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)
por: Zhang, Joshua, et al.
Publicado: (2023)

Dual Inhibition of KRAS(G12D) and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
por: Gulay, Kevin Christian Montecillo, et al.
Publicado: (2023)

Loss of Cadherin-11 in pancreatic ductal adenocarcinoma alters tumor-immune microenvironment
por: Sebastian, Aimy, et al.
Publicado: (2023)

KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence
por: Amintas, Samuel, et al.
Publicado: (2022)

Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma
por: Kong, Yao, et al.
Publicado: (2023)

Metabolomics based predictive classifier for early detection of pancreatic ductal adenocarcinoma
por: Unger, Keith, et al.
Publicado: (2018)

Integrative analysis of metabolome and gut microbiota in Patients with pancreatic ductal adenocarcinoma
por: Guo, Xiaodong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o5dqtgnq828l7eli061pvt2e9h